What's Happening?
Calyxo, Inc. presented six new abstracts at the European Association of Urology Annual Congress, highlighting the CVAC System's effectiveness in kidney stone treatment. The system demonstrated consistently low residual stone volume, leading to greater
procedural efficiency and reduced healthcare costs. A two-year health economics analysis revealed a 64% reduction in follow-up healthcare costs, saving an average of $3,464 per patient. The CVAC System's superior aspiration performance compared to suction sheaths was also noted, with studies receiving Best Abstract Presentation honors.
Why It's Important?
The CVAC System's ability to reduce residual stone volume and healthcare costs has significant implications for the treatment of kidney stones, a condition affecting 10% of the U.S. population. By improving procedural efficiency and reducing follow-up costs, the system offers a promising solution to the economic burden associated with kidney stone treatment, estimated to reach $4.1 billion annually by 2030. This advancement could lead to better patient outcomes and lower healthcare expenses, benefiting both patients and the healthcare system.
